Want to see JP:206A full AI Analyst Report?
206A Stock Chart & Stats
¥160.00
-¥4.00(-1.25%)
At close: 4:00 PM EST
¥160.00
-¥4.00(-1.25%)
Day’s Range― - ―
52-Week Range¥125.00 - ¥279.00
Previous CloseN/A
Volume305.30K
Average Volume (3M)2.26M
Market Cap
¥6.29B
Enterprise Value¥2.99K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.56
Shares Outstanding36,989,000
10 Day Avg. Volume1,556,930
30 Day Avg. Volume2,256,993
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)2.27
Price to Sales (P/S)9.06
P/FCF Ratio-4.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRapid top-line expansion indicates increasing commercial or partnership activity and provides a stronger base for future operating leverage, although the company must convert this growth into sustainable profitability.
Debt-Free Balance SheetA debt-free balance sheet reduces interest and refinancing pressure, preserving flexibility to fund drug discovery and development. This is especially valuable for a loss-making biotechnology company facing uncertain development timelines.
Partnering And Licensing ModelA partnering-led model can provide external funding and multiple potential revenue points across discovery, clinical, regulatory, and commercial stages, while allowing larger pharmaceutical partners to support development and commercialization.
Bears Say
Persistent Deep LossesPersistent operating and net losses show that revenue growth has not yet translated into economic sustainability. Continued high costs could delay break-even and increase dependence on partnerships, financing, or other external capital.
Accelerating Cash BurnNegative and volatile cash flow reduces the resources available for research and development and raises funding risk. If cash burn persists, the company may need additional financing or collaboration proceeds to maintain its pipeline.
Gross Margin CompressionMargin deterioration limits the benefit of revenue growth and suggests weaker earnings quality. Without improvement in gross economics and operating costs, higher sales may continue to produce losses rather than durable shareholder value.
PRISM BioLab Co. LTD News
206A FAQ
What was PRISM BioLab Co. LTD’s price range in the past 12 months?
PRISM BioLab Co. LTD lowest stock price was ¥125.00 and its highest was ¥279.00 in the past 12 months.
What is PRISM BioLab Co. LTD’s market cap?
PRISM BioLab Co. LTD’s market cap is ¥6.29B.
When is PRISM BioLab Co. LTD’s upcoming earnings report date?
PRISM BioLab Co. LTD’s upcoming earnings report date is Nov 13, 2026 which is in 79 days.
How were PRISM BioLab Co. LTD’s earnings last quarter?
PRISM BioLab Co. LTD released its earnings results on Aug 14, 2026. The company reported -¥6.56 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is PRISM BioLab Co. LTD overvalued?
According to Wall Street analysts PRISM BioLab Co. LTD’s price is currently Overvalued.
Does PRISM BioLab Co. LTD pay dividends?
PRISM BioLab Co. LTD does not currently pay dividends.
What is PRISM BioLab Co. LTD’s EPS estimate?
PRISM BioLab Co. LTD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PRISM BioLab Co. LTD have?
PRISM BioLab Co. LTD has 36,989,000 shares outstanding.
What happened to PRISM BioLab Co. LTD’s price movement after its last earnings report?
PRISM BioLab Co. LTD reported an EPS of -¥6.56 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.19%.
Which hedge fund is a major shareholder of PRISM BioLab Co. LTD?
Currently, no hedge funds are holding shares in JP:206A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PRISM BioLab Co. LTD
PRISM BioLab Co., LTD. engages in the research and development of pharmaceuticals using its proprietary drug discovery platform, PepMetics Technology. The company's technology focuses on creating peptide mimetic small molecules designed to mimic α-helix or β-turn peptides, which are essential for protein-protein interactions. Through its platform, PRISM aims to discover drugs for what were previously considered 'undruggable targets,' with a pipeline including candidates for cancer and fibrotic diseases.
Technical Analysis
StemRIM Inc.
―
CellSource Co., Ltd.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―